Genomic landscape of acquired resistance to third‐generation <i>EGFR</i> tyrosine kinase inhibitors in <i>EGFR</i> T790M‐mutant non–small cell lung cancer

Abstract

Resistance acquired after third-generation EGFR TKIs is associated with diverse pathways; however, treatment with osimertinib is primarily associated with a loss of EGFR T790M and the subsequent emergence of EGFR-independent resistance mechanisms.